CB1 vs CB2 Receptors: Understanding How Cannabis Interacts with the Body

What Are Cannabinoid Receptors?

• Cannabinoid receptors are G-protein coupled receptors that form part of the endocannabinoid system (ECS)
• Two primary subtypes have been identified: CB1 (discovered 1990) and CB2 (discovered 1993)
• Both receptors respond to endogenous cannabinoids (anandamide, 2-AG) and phytocannabinoids (THC, CBD)
• Additional cannabinoid-related receptors include GPR55, GPR18, and TRPV1 channels
• Understanding receptor pharmacology is essential for predicting how different cannabis products will act clinically

Cannabinoid receptors are the molecular interface through which cannabis interacts with human physiology. The two principal receptors — CB1 and CB2 — have distinct distributions throughout the body and produce markedly different effects when activated. This distinction has major implications for how medical cannabis is prescribed and which conditions it is most likely to benefit.

CB1 Receptors: The Brain and Central Nervous System

• CB1 receptors are among the most abundant G-protein coupled receptors in the mammalian brain
• They are concentrated in the hippocampus (memory), cerebellum (motor control), basal ganglia (movement), and prefrontal cortex (mood)
• Peripheral CB1 receptors are found in the gut, liver, lungs, and reproductive organs
• THC produces its psychoactive effects predominantly via CB1 agonism in the central nervous system
• CB1 activation inhibits neurotransmitter release — reducing pain signals, spasm, and hyperexcitability

CB1 receptor activation is responsible for the majority of cannabis’s well-known psychoactive and analgesic effects. When THC binds to CB1 receptors in the brain, it suppresses the release of excitatory neurotransmitters — producing analgesia, anti-spasm, anti-nausea, and appetite-stimulating effects. This mechanism underpins the use of THC-containing preparations for neuropathic pain, MS spasticity, and chemotherapy-induced nausea.

CB2 Receptors: The Immune System and Inflammation

• CB2 receptors are expressed primarily on immune cells: macrophages, B-cells, natural killer cells, and microglia
• They are also found in peripheral tissues including the gut, bone, liver, and skin
• CB2 activation modulates inflammatory cytokine production and immune cell migration
• CBD is a partial agonist at CB2 — contributing to its anti-inflammatory and immunomodulatory properties
• CB2 upregulation is observed in inflamed or damaged tissue — making it a key therapeutic target

CB2 receptors represent the immunological arm of the endocannabinoid system. Activation of CB2 reduces the production of pro-inflammatory cytokines (TNF-alpha, IL-6) and modulates the migration of immune cells to sites of injury. This explains why cannabinoids — particularly CBD — show promise in inflammatory conditions such as Crohn’s disease, rheumatoid arthritis, and neuroinflammatory disorders.

Clinical Implications: Targeting Receptors in Prescribing

• Conditions driven by central nervous system pathology (neuropathic pain, MS, epilepsy) benefit most from CB1 modulation
• Inflammatory conditions (IBD, arthritis, autoimmune disease) benefit more from CB2 engagement
• Many conditions benefit from modulating both receptor subtypes simultaneously
• The entourage effect suggests that full-spectrum preparations targeting both receptors outperform isolates
• Research into CB2-selective agonists is ongoing — aiming to deliver anti-inflammatory benefits without CB1-mediated psychoactivity

For prescribers and patients alike, understanding the CB1/CB2 distinction helps explain why different cannabis preparations produce different effects. A high-THC product powerfully activates CB1 — ideal for severe neuropathic pain. A high-CBD product engages CB2 more selectively — better suited to inflammatory conditions. Most medical cannabis prescribing balances both receptor systems to achieve the optimal therapeutic outcome.